Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 31, 2012. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure metrics:
- Shares Purchased: 1,100,000 ordinary shares on July 31, 2012.
- Price Range: Highest price paid was 1,477.5 pence per share; lowest price paid was 1,458.5 pence per share.
- Treasury Holdings (Settled): 479,907,927 shares (8.77% of total issued share capital).
- Treasury Holdings (Including Unsettled): 483,707,927 shares (9.69% of current total voting rights).
- Shares in Issue: 4,989,649,952 shares (excluding treasury shares).
Material Changes
The primary material change reported is the increase in the company's treasury share holdings following the purchase of 1,100,000 shares. This transaction increased the percentage of total voting rights held in treasury from the prior level to 9.69% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,989,649,952) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated treasury share count (483,707,927 including unsettled) to assess the impact on total voting rights.
- Review the price paid per share (1,458.5 to 1,477.5 pence) against market prices on July 31, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.